At the news
? NEUTRALIMPACT 2/10 COURT-RULING filed Jul 14, 2026 at 20:00 ET
A federal magistrate judge partially granted and partially denied Corcept Therapeutics' motion to compel discovery from Teva's CEO Richard Francis. Teva's CEO must sit for a limited two-hour deposition regarding his critique of Teva's generic mifepristone promotion strategies, but Teva is not required to produce his custodial documents. This is a routine procedural discovery ruling in an ongoing antitrust case with no immediate financial impact.
- Teva is the plaintiff in an antitrust case against Corcept regarding generic mifepristone for Cushing's syndrome.
- Corcept sought to depose Teva's CEO Richard Francis and obtain his documents; the court granted a limited 2-hour deposition on one topic and denied document production.
- The deposition is limited to Mr. Francis's critique of Teva's strategy for promoting generic mifepristone and his ideas for solutions.
- Fact discovery in the case closed on May 15, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access